$2.05
12.02% day before yesterday
NYSE, Jul 18, 10:01 pm CET
ISIN
US1420381089
Symbol
CRBU
Sector
Industry

Caribou Biosciences Stock price

$2.05
+0.77 60.16% 1M
+0.52 33.99% 6M
+0.46 28.93% YTD
-0.35 14.58% 1Y
-4.68 69.54% 3Y
-14.27 87.44% 5Y
-14.27 87.44% 10Y
-14.27 87.44% 20Y
NYSE, Closing price Fri, Jul 18 2025
+0.22 12.02%
ISIN
US1420381089
Symbol
CRBU
Sector
Industry

Key metrics

Basic
Market capitalization
$190.7m
Enterprise Value
$-17.8m
Net debt
positive
Cash
$208.5m
Shares outstanding
93.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
19.2 | 17.4
EV/Sales
negative | negative
EV/FCF
0.1
P/B
0.9
Financial Health
Equity Ratio
80.7%
Return on Equity
-59.0%
ROCE
-66.7%
ROIC
-287.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$9.9m | $10.9m
EBITDA
$-159.1m | $-158.1m
EBIT
$-163.5m | $-178.9m
Net Income
$-147.9m | $-135.7m
Free Cash Flow
$-142.2m
Growth (TTM | estimate)
Revenue
-70.3% | 9.6%
EBITDA
-25.0% | 2.8%
EBIT
-24.9% | -7.4%
Net Income
-28.3% | 9.0%
Free Cash Flow
-25.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,604.6% | -1,444.6%
EBIT
-1,648.8%
Net
-1,490.8% | -1,240.0%
Free Cash Flow
-1,433.7%
More
EPS
$-1.6
FCF per Share
$-1.5
Short interest
12.3%
Employees
158
Rev per Employee
$60.0k
Show more

Is Caribou Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Caribou Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Caribou Biosciences forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Caribou Biosciences forecast:

Buy
86%
Hold
14%

Financial data from Caribou Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
9.92 9.92
70% 70%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 42 42
6% 6%
419%
- Research and Development Expense 132 132
10% 10%
1,330%
-159 -159
25% 25%
-1,604%
- Depreciation and Amortization 4.38 4.38
20% 20%
44%
EBIT (Operating Income) EBIT -164 -164
25% 25%
-1,648%
Net Profit -148 -148
28% 28%
-1,491%

In millions USD.

Don't miss a Thing! We will send you all news about Caribou Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Caribou Biosciences Stock News

Neutral
GlobeNewsWire
about 2 months ago
BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT.
Neutral
GlobeNewsWire
2 months ago
-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in  H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company's current operating plan into H2 2027 -- BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical com...
Neutral
GlobeNewsWire
2 months ago
BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT.
More Caribou Biosciences News

Company Profile

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Head office United States
CEO Rachel Haurwitz
Employees 158
Founded 2011
Website www.cariboubio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today